Oral riboflavin supplementation and sunlight exposure: A possible novel and accessible approach to stabilize progressive keratoconus

View at publisher Summarise with VIRAT
Authors: Edilana Sá Ribeiro, Natália Regnis L Ramalho, Isabela Spinelli Mota, Eron Gurgel Moreira, Camilla Valença Collier Padilha Pinto, Lucas Martins de Melo Alves, Marcela R. V. Oliveira, Taciana Mirely Maciel Higino, Camila Vieira Oliveira Carvalho Ventura, Jose Alvaro Pereira Gomes, Bruna V. Ventura, Walton Nosé
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PurposeTo evaluate the efficacy of oral riboflavin and sunlight exposure in stabilizing keratoconus progression.MethodsIn this prospective interventional study with a retrospective historical control group, patients with progressive keratoconus received 60 mg/day of oral riboflavin and 30 min/day of sunlight exposure for three months. A historical control group included patients with similar characteristics who were awaiting cross-linking or keratoplasty. Ophthalmological exams and corneal topography were conducted at baseline, 6 months, and 12 months post-treatment. A sub-analysis was performed for patients with corneal stromal thickness (CST) ≥ 400 µm and < 400 µm.ResultsFifty patients [91 eyes; 31 (62%) males] with a mean age of 18.7 ± 4.4 years (range, 11-31) and a mean maximum keratometry (Kmax) of 57.9 ± 8.3 D comprised the treatment group. Kmax flattened (-1.22 ± 4.78 D; P = 0.003) in treated eyes; however, it steepened (+0.32 ± 11.96 D; P = 0.455) in controls at 6 months. Keratoconus progression occurred in 27.5% of treated eyes versus 49.5% in controls (P = 0.002). Eyes with CST ≥ 400 µm had a 3.85-fold higher risk of progression in the control group than in treated eyes (95% CI: 1.6-9.3; P = 0.001).ConclusionAfter one year, 72.5% of treated eyes remained stable following the use of oral riboflavin and sunlight exposure, with a significantly lower risk of progression in eyes with normal CST.

Fields of Study & Subjects

Corneal surgery and disorders Ocular Infections and Treatments Ophthalmology and Visual Impairment Studies

Publication details

Journal / source
European Journal of Ophthalmology
Volume
36
Issue
5
Pages
1273–1282
Publication date
29 March 2026
Language
EN